Abstract
Congenital cytomegalovirus (HCMV) infection may cause significant fetal malformation, lifelong disease, and, in severe cases, fetal or neonatal death. Placental infection with HCMV is the major mechanism of mother-to-child transmission (MTCT) and fetal injury. Thus, any pharmaceutical antiviral interference to reduce viral load may reduce placental damage, MTCT, and fetal disease. However, there is currently no licensed HCMV antiviral for use during pregnancy. In this study, aciclovir and the HCMV-specific antivirals letermovir, maribavir, and cidofovir were compared with ganciclovir for antiviral effects in model systems of pregnancy, including first-trimester TEV-1 trophoblast cell cultures and third-trimesterex vivoplacental explant histocultures.
Funding Information
  • Australian-Germany Joint Research Cooperation Scheme (RG162050/RG192195)
  • Interdisciplinary Center for Clinical Research of the Faculty of Medicine of FAU (A88/MM-HS)
  • Go8-DAAD (54390135)
  • Wilhelm Sander-Stiftung (2018.121.1)
  • Department of Health, Australian Government | National Health and Medical Research Council (APP1127717)
  • Thrasher Research Fund (RG181876)

This publication has 39 references indexed in Scilit: